Compugen Ltd.

CGEN

Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.

Revenue
+107.0%
EPS
+12.5%
Free cash flow
−155.4%

Quarter to June 2026, against a year earlier

1.96 0.04 +2.08%
Market cap
$185.7M
P/E
5.2×
Fwd P/E
n/m
Dividend yield
—
F-score
7/9
ROIC
0.00%
Net debt / EBITDA
−4.7×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

— — — 7
ROE
0.00% 42.00% 0.00% 47.85%
ROA
(24.95%) 26.03% 26.68% 23.86%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(39.79%) 28.02% 30.08% 32.75%
Average Days of Receivables
149.74 11.95 11.75 20.27
Free Cash Flow per Share
0.00 1.09 0.00 0.42
Free Cash Flow
— 101.69 — 40.04
Other line items

Show all line items

Columns are period end dates